We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. Read More
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s multiple sclerosis (MS) drug Zeposia (ozanimod) for use by the National Health Service over cost concerns. Read More
Biogen’s experimental gene therapy, cotoretigene toliparvovec, failed to show efficacy in a phase 2/3 study of patients suffering from a rare, inherited retinal disease. Read More
A UK study has shown that individuals over 80 years old had significantly higher antibody responses when given their second Pfizer/BioNTech vaccine dose after 12 weeks as opposed to the standard three-week interval. Read More
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist that offsets the negative effects of overactivation of the mineralocorticoid receptor. Read More
Inovio said the results from the 400-person phase 2 study will help answer the agency’s questions and that the phase 3 trial will advance once the hold is lifted. Read More